Revenue growth during the quarter was driven by Finished Dosages (FD) segment in North America and Europe.
Profit before tax (PBT) jumped 32.36% YoY to Rs 202.23 crore during the quarter.
EBITDA stood at Rs 308.1 crore, registering the growth of 34% compared with Rs 230.3 crore in Q3 FY25. EBITDA margin improved to 22% in Q3 FY26 as against 20% in Q3 FY25.
For Q3 FY26, Finished Dosages, Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/CDMO contributed 76%, 11%, 11%, and 2% of revenue from operations, respectively.
Net debt stood at Rs 1,015.1 crore and Net debt to EBITDA at 0.91x in Q3 FY26.
Krishna Prasad Chigurupati, chairman & managing director of Granules India said, “Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives and we are well positioned for sustained growth momentum. Our strong financial performance, on-going R&D investments, combined with advances in ESG stewardship and our expanding global supply footprint, reinforces our commitment to building a resilient, innovation-led pharmaceutical platform that delivers long-term value for all stakeholders.”
Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).
The scrip declined 1.09% to end at Rs 564.95 on the BSE.